| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/24/2003 | US20030077614 Nucleic acids for inhibiting hairless protein expression and methods of use thereof |
| 04/24/2003 | US20030077606 Nucleic acids, proteins, and antibodies |
| 04/24/2003 | US20030077602 Nucleic acids, proteins, and antibodies |
| 04/24/2003 | US20030077595 Methods and compositions for enhancing sensitivity in the analysis of biological-based assays |
| 04/24/2003 | US20030077594 Nucleotide sequences coding polypeptide for use in the treatment of cancer and nervous system disorders |
| 04/24/2003 | US20030077593 Nucleotide sequences coding polypeptide for use in the treatment of cancer and nervous system disorders |
| 04/24/2003 | US20030077590 Nucleotide sequences coding polypeptides for use in te diagnosis and treatment of lymphoma and leukemia |
| 04/24/2003 | US20030077587 Nucleotide sequences coding polypeptide for use in diagnosis and treatment of vision defects |
| 04/24/2003 | US20030077585 Nucleotide sequences coding polypeptide for use in the diagnosis, detection, prevention and treatment of bacterial infection |
| 04/24/2003 | US20030077565 Preservation of corneal graft in vitro; obtain graft, incubate with antisense oligonucleotides in solution, monitor viability of graft tissue |
| 04/24/2003 | US20030077564 Amplification of neural cell viability in brain or spinal cord tissue after brain or spinal cord injury; obtain tissue, apply nutrient broth, monitor cell viability |
| 04/24/2003 | US20030077334 Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanism for normal and transformed cells |
| 04/24/2003 | US20030077318 Activation lymphocytes; therapy for aids, cancer; immobilization on solid support |
| 04/24/2003 | US20030077301 Topically administering to a localized region affected by the inflammatory dermatosis on a patient skin a formulation containing a active agent,and a permeation enhancing base to enhance the flux of active agent through skin without damage |
| 04/24/2003 | US20030077297 Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| 04/24/2003 | US20030077291 Active enamel matrix substance, such as an amelogenin, a processed amelogenin product, or a metabolite can be used in treating conditions in a mammal which present an imbalance in its native immune resposne to external or internal stimuli |
| 04/24/2003 | US20030077290 Non-anaphylactic forms of grass pollen Phl p 6 allergen and their use |
| 04/24/2003 | US20030077286 A T cell receptor ligand which substantially inhibits at least one T cell effector response evoked by fully active peptide-MHC(major histocompatibility complex) available to respond T cells |
| 04/24/2003 | US20030077283 Topical treatment of psoriasis using neutralizing antibodies to IL-8 |
| 04/24/2003 | US20030077280 Monoclonal antibody which specifically recognizes and forms complex with protein located on surface of activated T cells and thereby inhibits T cell activation of B cells |
| 04/24/2003 | US20030077279 Methods for treating vascular disease by inhibiting toll-like receptor-4 |
| 04/24/2003 | US20030077278 Novel human beta2 integrin alpha subunit |
| 04/24/2003 | US20030077276 Expression vectors constructed by inserting antibody heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing rat onoclonal antibody reacting with ganglioside gm2 |
| 04/24/2003 | US20030077275 Chimeric antibody specific to human CD4 which comprises the variable heavy and light chain sequences of an Old World monkey monoclonal antibody produced against human CD4 and human constant heavy and light domain sequences |
| 04/24/2003 | US20030077271 Use of coagulation factor VII-activating protease for the prophylaxis and therapy of vasoproliferative disorders |
| 04/24/2003 | US20030077269 To increase levels of skin and mucosal ceramides; dermatological and cosmetic compositions containing same which are suitable for topical application |
| 04/24/2003 | US20030077268 Recombinant bacterial cells for delivery of PNP to tumor cells |
| 04/24/2003 | US20030077267 Purified forms of DNase |
| 04/24/2003 | US20030077266 Anti-cancer compositions |
| 04/24/2003 | US20030077262 Methods and compositions for modulating apoptosis |
| 04/24/2003 | US20030077261 Increasing in vivo concentration of A beta peptide, or biologically active fragments or variants thereof within a patient suffering from angiogenic diseases, conditions, or processes |
| 04/24/2003 | US20030077260 Hybrid matrix implants and explants |
| 04/24/2003 | US20030077258 Comprising one or more chondroitin sulfate proteoglycan (CSPG)-degrading enzymes that promote axonal penetration into damaged nerve tissue and nerve graft |
| 04/24/2003 | US20030077255 Compositions of bacteria and alpha-lactalbumin and uses thereof |
| 04/24/2003 | US20030077254 A drug mixture comprising a transfer factor polypeptides with zinc and fatty acids; veterinary medicine |
| 04/24/2003 | US20030077253 Implantable or insertable therapeutic agent delivery device |
| 04/24/2003 | US20030077252 Vaccination against plaque forming diseases; inhibiting aggregation of amyloid in mammal and/or to cause disaggregation of amyloid; treating brain disorder, Alzheimer's disease |
| 04/24/2003 | US20030077250 Method for selectively transducing pathologic mammalian cells using a tumor suppressor gene |
| 04/24/2003 | US20030077248 Treating cancer with a culture product from a non-naturally occurring antigen-presenting cell; polyclonal antibodies expression |
| 04/24/2003 | US20030077247 Chemokines as adjuvants of immune response |
| 04/24/2003 | US20030077246 TNFr/OPG-like molecules and uses thereof |
| 04/24/2003 | US20030077236 An enzyme extract use as sunscreen agent, able degrading melanin |
| 04/24/2003 | US20030077229 Aqueous polar solvent, active compound, and flavoring agents; propellant-free |
| 04/24/2003 | US20030077228 Polar solvent 30-99.69%, active compound 0.001-60%, and f lavoring agent 0.1-10%; propellant free |
| 04/24/2003 | US20030077227 Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| 04/24/2003 | US20030075470 Transdermal/transmucosal patch packaging |
| 04/24/2003 | US20030075187 Mixed chimerism and tolerance |
| 04/24/2003 | US20030075172 Method and apparatus for dispensing inhalator medicament |
| 04/24/2003 | CA2775218A1 Intact minicells as vectors for dna transfer and gene therapy in vitro and in vivo |
| 04/24/2003 | CA2727642A1 Synthesis of cyclosporin analogs |
| 04/24/2003 | CA2494706A1 Chimeric glycosylphosphatidylinositol containing peptides |
| 04/24/2003 | CA2476675A1 Neutrokine-alpha and neutrokine-alpha splice variant |
| 04/24/2003 | CA2463994A1 Carbocyanine dyes for tandem, photodiagnostic and therapeutic applications |
| 04/24/2003 | CA2463991A1 Therapeutic composition and use |
| 04/24/2003 | CA2463925A1 Bone anti-resorptive compounds |
| 04/24/2003 | CA2463911A1 Tumor targeted photodiagnostic-phototherapeutic agents |
| 04/24/2003 | CA2463908A1 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| 04/24/2003 | CA2463906A1 Pathological tissue detection and treatment employing targeted benzoindole optical agents |
| 04/24/2003 | CA2463898A1 Methods and materials for targeting and affecting selected cells |
| 04/24/2003 | CA2463816A1 Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
| 04/24/2003 | CA2463769A1 Composition and method for treating diabetes |
| 04/24/2003 | CA2463729A1 Treatment of infectious disease using interleukin-1 beta converting enzyme (ice)/ced-3 family inhibitors |
| 04/24/2003 | CA2463682A1 Method of reducing type 2 diabetes in high risk patients |
| 04/24/2003 | CA2463676A1 Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans |
| 04/24/2003 | CA2463674A1 Controlled release capsules for providing both pulsed burst and controlled release of drugs to the rumen of ruminant animals over an extended time period |
| 04/24/2003 | CA2463655A1 Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi) |
| 04/24/2003 | CA2463649A1 Rankl mimics and uses thereof |
| 04/24/2003 | CA2463641A1 Antisense antiviral agent and method for treating ssrna viral infection |
| 04/24/2003 | CA2463578A1 Differentially expressed genes associated with obesity and type 2 diabetes |
| 04/24/2003 | CA2463473A1 Targeted therapeutic proteins |
| 04/24/2003 | CA2463459A1 Novel use of pulmonary surfactant |
| 04/24/2003 | CA2463395A1 Therapeutic agents for low hdl-cholesterolemia |
| 04/24/2003 | CA2463249A1 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| 04/24/2003 | CA2463020A1 Use of gp130 activators in diabetic neuropathy |
| 04/24/2003 | CA2463003A1 Dimerized growth factor and materials and methods for producing it |
| 04/24/2003 | CA2462785A1 Kinases and phosphatases |
| 04/24/2003 | CA2462713A1 Additive cytoprotective effects of two bioactive regions of pro-opiomelanocortin hormone |
| 04/24/2003 | CA2462642A1 Use of aplidine for the treatment of pancreatic cancer |
| 04/24/2003 | CA2462639A1 Kahalalide compounds for use in cancer therapy |
| 04/24/2003 | CA2462588A1 Ngzipa, ngzipd, pgzipa, and pgzipd polynucleotides and polypeptides and uses thereof |
| 04/24/2003 | CA2461836A1 Detection and treatment of intravascular lesions |
| 04/24/2003 | CA2461818A1 Treatment and diagnosis of insulin resistant states |
| 04/24/2003 | CA2461740A1 Synthesis of cyclosporin analogs |
| 04/24/2003 | CA2461556A1 Compositions and methods for delivery of microparticles of poorly water soluble drugs and methods of treatment |
| 04/24/2003 | CA2461542A1 Gap junctions and endothelial-derived hyperpolarizing factor (edhf) |
| 04/24/2003 | CA2461245A1 Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders |
| 04/24/2003 | CA2461170A1 Peptidyl ketones as inhibitors of dpiv |
| 04/24/2003 | CA2460685A1 Cyclosporine analogue mixtures and their use as immunomodulating agents |
| 04/24/2003 | CA2460132A1 Use of a copolymer to produce a galenic form containing a peptide or a protein as active agent |
| 04/24/2003 | CA2454578A1 Modified human thymic stromal lymphopoietin |
| 04/24/2003 | CA2453264A1 Novel drug targets for arthritis |
| 04/23/2003 | EP1304379A2 Humanised antibody against CD18 |
| 04/23/2003 | EP1304378A1 ARL-2 for fertility control |
| 04/23/2003 | EP1304335A2 Hepatitis C virus protease |
| 04/23/2003 | EP1304327A2 Glutamine-thiazolidide and -pyrrolidide and their use as dipeptidylpeptidase IV inhibitors |
| 04/23/2003 | EP1304123A2 Methods for the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| 04/23/2003 | EP1304119A2 Method for preventing and treating hearing loss using a neurturin protein product |
| 04/23/2003 | EP1304118A2 Therapeutic uses and formulations for BPI protein products. |
| 04/23/2003 | EP1304117A1 Remedies for bone diseases |
| 04/23/2003 | EP1304116A1 New class of bioactive glycoprotein |